The Immune System and the Remodeling Infarcted Heart: Cell Biological Insights and Therapeutic OpportunitiesFrangogiannis, Nikolaos G. MDJournal of Cardiovascular Pharmacology: March 2014 - Volume 63 - Issue 3 - p 185–195 doi: 10.1097/FJC.0000000000000003 Invited Review Article Abstract Author Information Abstract: Extensive necrosis of ischemic cardiomyocytes in the infarcted myocardium activates the innate immune response triggering an intense inflammatory reaction. Release of danger signals from dying cells and damaged matrix activates the complement cascade and stimulates Toll-like receptor/interleukin-1 signaling, resulting in the activation of the nuclear factor-κB system and induction of chemokines, cytokines, and adhesion molecules. Subsequent infiltration of the infarct with neutrophils and mononuclear cells serves to clear the wound from dead cells and matrix debris, while stimulating reparative pathways. In addition to its role in repair of the infarcted heart and formation of a scar, the immune system is also involved in adverse remodeling of the infarcted ventricle. Overactive immune responses and defects in suppression, containment, and resolution of the postinfarction inflammatory reaction accentuate dilative remodeling in experimental models and may be associated with chamber dilation, systolic dysfunction, and heart failure in patients surviving a myocardial infarction. Interventions targeting the inflammatory response to attenuate adverse remodeling may hold promise in patients with myocardial infarction that exhibit accentuated, prolonged, or dysregulated immune responses to the acute injury. Wilf Family Cardiovascular Research Institute, Department of Medicine, Division of Cardiology, Albert Einstein College of Medicine, Bronx, NY. Reprints: Nikolaos G. Frangogiannis, MD, The Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, 1300 Morris Park Avenue Forchheimer G46B, Bronx, NY 10461 (e-mail: firstname.lastname@example.org). Supported by National Institutes of Health grants (R01 HL76246 and R01 HL85440). The authors report no conflicts of interest. Received March 29, 2013 Accepted July 16, 2013 © 2014 by Lippincott Williams & Wilkins.